Table 7.
Factors affecting occurrence of severe CRS by logistic regression analysis.
| Items | Logistic regression model | |||
|---|---|---|---|---|
| P value | OR | 95% CI | ||
| Lower | Higher | |||
| Univariate logistic regression | ||||
| Age (≥18 vs. <18 years) | 0.096 | 3.325 | 0.809 | 13.674 |
| Gender (male vs. female) | 0.721 | 1.269 | 0.343 | 4.696 |
| Number of previous chemotherapies (≥4 vs. <4) | 0.759 | 0.816 | 0.223 | 2.992 |
| Refractory disease (yes vs. no) | 0.005 | 8.250 | 1.895 | 35.910 |
| Relapsed disease (yes vs. no) | 0.148 | 0.174 | 0.016 | 1.857 |
| Bone marrow blasts (≥5% vs. <5%) | 0.675 | 1.382 | 0.305 | 6.255 |
| Extramedullary disease (yes vs. no) | 0.334 | 0.525 | 0.142 | 1.943 |
| CNSL (yes vs. no) | 0.334 | 0.525 | 0.142 | 1.943 |
| BCR/ABL1 (positive vs. negative) | 0.256 | 0.417 | 0.092 | 1.888 |
| SH2B3 mutation (positive vs. negative) | 0.171 | 0.350 | 0.078 | 1.573 |
| PAX5 mutation (positive vs. negative) | 0.236 | 0.430 | 0.106 | 1.739 |
| WBC (≥30 × 109/L vs. <30 × 109/L) | 0.082 | 0.300 | 0.077 | 1.163 |
| Lymphodepletion regimens (Flu + Cy vs. non-Flu + Cy) | 0.784 | 1.214 | 0.303 | 4.867 |
| CAR-T cells (anti-CD19 + CD22 vs. anti-CD19) | 0.792 | 0.833 | 0.215 | 3.230 |
| Multivariate logistic regression | ||||
| Refractory disease (yes vs. no) | 0.005 | 12.599 | 2.187 | 72.587 |
| WBC (≥30 × 109/L vs. <30 × 109/L) | 0.047 | 0.169 | 0.029 | 0.978 |
Factors affecting occurrence of severe CRS were determined by univariate and multivariate Logistic regression analysis with Forward Stepwise (Conditional) method. P value <0.05 was considered significant.
CRS cytokine release syndrome, CR complete remission, MRD minimal residual disease, CNSL central nervous system leukemia, WBC white blood cell, Flu fludarabine, Cy cyclophosphamide, CAR-T chimeric antigen receptor T cells, OR odds ratio, CI confidence interval.